Last checked at 
LONDON (Alliance News) - PureTech Health PLC said Tuesday it has launched a new company, called Alivio Therapeutics, which is developing technology to treat chronic and acute inflammatory disorders.
PureTech owns around 92% of Alivio Therapeutics, which was co-founded by PureTech Non-Executive Director and Scientific Advisory Board Member Robert Langer and Harvard Medical School's Brigham and Women's Hospital Associate Professor Jeff Karp.
PureTech said Alivio is developing the new technology to help overcome challenges in the field, namely significant side effects and failure to adequately control diseases. The new technology is based on an innovative hydrogel material that is designed to adhere to and deliver drugs to inflamed tissue based on the degree of inflammation, PureTech said.
"What differentiates this technology is its potential to safely adhere to inflamed tissue while controlling drug release based on the amount of inflammation," said Langer.
"These unique properties hold promise to change the way inflammatory disease is treated in a variety of indications," Langer added.
PureTech is holding its first capital markets meeting as a London-listed company on Tuesday.
Shares in PureTech were up 0.2% at 123.00 pence on Tuesday morning.
By Hannah Boland; hannahboland@alliancenews.com; @Hannaheboland
Copyright 2016 Alliance News Limited. All Rights Reserved.
